Renaissance Technologies (RenTech)'s LCTX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 2.13 M shares of Lineage Cell Therapeutics, Inc. (LCTX) worth $3.36 M, representing 0.01% of the portfolio. First purchased in 2020-Q1, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in LCTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 2.09 M shares. Largest reduction occurred in Q4 2020, reducing 437,806 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Lineage Cell Therapeutics (LCTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Lineage Cell Therapeutics (LCTX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -279,700 | Reduce 11.63% | 2.13 M | $1.58 |
| Q4 2025 | +499,167 | Add 26.19% | 2.4 M | $1.67 |
| Q3 2025 | -66,702 | Reduce 3.38% | 1.91 M | $1.69 |
| Q2 2025 | -319,046 | Reduce 13.92% | 1.97 M | $0.91 |
| Q1 2025 | +8,309 | Add 0.36% | 2.29 M | $0.45 |
| Q4 2024 | +2.09 M | Add 1058.33% | 2.28 M | $0.50 |
| Q3 2024 | -386,522 | Reduce 66.23% | 197,100 | $0.91 |
| Q2 2024 | +53,022 | Add 9.99% | 583,622 | $1.00 |
| Q1 2024 | +380,600 | Add 253.73% | 530,600 | $1.48 |
| Q4 2023 | +90,300 | Add 151.26% | 150,000 | $1.09 |
| Q3 2023 | +3,800 | Add 6.80% | 59,700 | $1.17 |
| Q2 2023 | +55,900 | New Buy | 55,900 | $0.00 |
| Q1 2021 | -23,000 | Sold Out | 0 | $0.00 |
| Q4 2020 | -437,806 | Reduce 95.01% | 23,000 | $1.74 |
| Q3 2020 | -30,894 | Reduce 6.28% | 460,806 | $0.94 |
| Q2 2020 | +223,300 | Add 83.20% | 491,700 | $0.87 |
| Q1 2020 | +268,400 | New Buy | 268,400 | $0.83 |
Renaissance Technologies (RenTech)'s Lineage Cell Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Lineage Cell Therapeutics, Inc. (LCTX) in Q1 2020, acquiring 268,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Lineage Cell Therapeutics, Inc. (LCTX) for 17 quarters since Q1 2020.
Renaissance Technologies (RenTech)'s largest addition to Lineage Cell Therapeutics, Inc. (LCTX) was in Q4 2024, adding 2,283,072 shares worth $1.15 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 2,125,100 shares of Lineage Cell Therapeutics, Inc. (LCTX), valued at approximately $3.36 M.
As of the Q1 2026 filing, Lineage Cell Therapeutics, Inc. (LCTX) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Lineage Cell Therapeutics, Inc. (LCTX) was 2,404,800 shares, as reported at the end of Q4 2025.